Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

STRATA Skin Sciences (SSKN) Current Deferred Revenue (2016 - 2025)

STRATA Skin Sciences' Current Deferred Revenue history spans 14 years, with the latest figure at $2.6 million for Q3 2025.

  • For Q3 2025, Current Deferred Revenue rose 5.37% year-over-year to $2.6 million; the TTM value through Sep 2025 reached $2.6 million, up 5.37%, while the annual FY2024 figure was $2.2 million, 5.71% up from the prior year.
  • Current Deferred Revenue for Q3 2025 was $2.6 million at STRATA Skin Sciences, up from $2.4 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.8 million in Q3 2021 and bottomed at $2.1 million in Q4 2023.
  • The 5-year median for Current Deferred Revenue is $2.4 million (2024), against an average of $2.6 million.
  • The largest annual shift saw Current Deferred Revenue surged 132.84% in 2021 before it decreased 25.12% in 2023.
  • A 5-year view of Current Deferred Revenue shows it stood at $3.3 million in 2021, then decreased by 15.43% to $2.8 million in 2022, then fell by 23.69% to $2.1 million in 2023, then increased by 5.71% to $2.2 million in 2024, then rose by 13.83% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for SSKN's Current Deferred Revenue are $2.6 million (Q3 2025), $2.4 million (Q2 2025), and $2.2 million (Q1 2025).